Diamics

Diamics was a medical technology company that specialized in the development of molecular diagnostic systems for cancer screening, with a primary focus on cervical cancer. The company's core technology, the CerviScan system, aimed to provide a more accurate and cost-effective alternative to traditional Pap smears by integrating cytology with molecular markers. Diamics also worked on the MapTest, a molecular diagnostic tool intended for broader oncology applications. Headquartered in Novato, California, the company was publicly traded but eventually ceased operations following financial difficulties. Its products were designed to streamline the diagnostic workflow for clinicians while improving patient outcomes through earlier detection.